Immunosuppressor Control as a Modality of Cancer Treatment: Effect of Plasma Adsorption with Staphylococcus aureus Protein A

  • Prasanta K. Ray
Part of the Contemporary Topics in Immunobiology book series (CTI, volume 15)


The concept of immunologic manipulation in the treatment of cancer is nothing new. Although it dates back to the late nineteenth and early twentieth centuries (Coley, 1891, 1893), little attention was paid to it for a long time. However, interest was revived with the discovery of tumor-associated antigens (TAA) on spontaneously occurring animal and human tumors (Old and Boyse, 1964; Old and Stockert, 1977; Möller, 1964; Hewitt et al., 1976; Witz, 1977; Garrett et al., 1977; Herberman, 1977; Prehn, 1976; Hewitt, 1978; Baker et al., 1978; Billing et al., 1978). These antigens are not usually found on normal cells, at least at detectable levels, and they are therefore considered to be tumor-associated. Among the various types of antigens detected so far on the cell membrane of tumor cells, besides tumor-specific antigens, are embryonic antigen, organ-specific antigen, and histocompatibility antigen (Gupta and Morton, 1983; F. Martin and Martin, 1970; Purves and Geddes, 1972; Sengupta and Ray, 1979; Ray and Seshadri, 1980, 1981). Against those antigens, both humoral and cell-mediated immune responses have been demonstrated in vivo and in vitro, implicating the “foreignness” of these antigens. An interesting review by Gupta and Morton (1983) discussed the characteristics of tumor antigens associated with animal and human tumors; the dynamic aspect of the immune response to tumor antigens; and their role in immune surveillance, rejection, and enhancement of tumor growth.


Immune Complex Spleen Cell Suppressor Cell Suppressor Cell Activity Antitumor Antibody 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Agnello, V., 1981, Immune complex assays: The first 10 years, Ann. Intern. Med. 94: 266.PubMedGoogle Scholar
  2. Albo, V., Krivit, W., and Hartman, J., 1978, Fresh plasma as adjuvant to the chemotherapy of acute lymphatic leukemia in children, Proc. Am. Assoc. Cancer Res. 9: 104.Google Scholar
  3. Alexander, P., 1974, Escape from immune destruction by the host through shedding of surface antigens: Is this a characteristic shared by malignant and embryonic cells? Cancer Res. 34: 2077.PubMedGoogle Scholar
  4. Amlot, P. L., Pussel, B., Slaney, J. M., and Williams, B. D., 1978, Correlation between immune complexes and prognostic factors in Hodgkin’s disease, Clin. Exp. Immunol. 31: 166.PubMedGoogle Scholar
  5. Anderson, R. J., McBridge, C. M., and Hersch, E. M., 1972, Lympocyte blastogenic responses to cultured allogeneic tumor cells in vitro. Cancer Res. 32: 988.PubMedGoogle Scholar
  6. Andrews, S., Congdon, G. A., and Edwards, C. C., 1967, Preliminary trials of clinical immunotherapy, Cancer Res. 27: 2535.PubMedGoogle Scholar
  7. Attlic, M. A. M., and Weiss, D. W., 1966, Immunology of spontaneous mammary carcinomas in mice. V. Acquired tumor resistance and enhancement in strain A mice infected with mammary tumor virus, Cancer Res. 26: 1787.Google Scholar
  8. Baird, L. G., and Kaplan, A. M., 1977a, Macrophage regulation of mitogen-induced histogenesis. I. Demonstration of inhibitor cells in the spleens and peritoneal exudate of mice, Cell. Immunol. 28: 22.PubMedGoogle Scholar
  9. Baird, L. G., and Kaplan, A. M., 1977b, Macrophage regulation of mitogen-induced blasto-genesis. II. Mechanism of inhibitor cell, Cell. Immunol. 28: 36.PubMedGoogle Scholar
  10. Baker, M. A., Falk, J. A., and Taub, R. M., 1978, Immunotherapy of human acute leukemia: Antibody response to leukemia associated antigens, Blood 52: 469.PubMedGoogle Scholar
  11. Baldwin, R. W., Price, M. R., Robins, R. A., 1972, Blocking lymphocyte-mediated cytotoxicity for rap hepatoma cells by tumor specific antigen-antibody complexes, Nature 238: 185.Google Scholar
  12. Baldwin, R. W., Embleton, M. J., Price, M. R., and Robins, R. A., 1974, Immunity in the tumor-bearing host and its modification by serum factor, Cancer 34: 1452.PubMedGoogle Scholar
  13. Bandyopadhyay, S. K., and Ray, P. K., 1985, Introduction of bacterial components in post- adsorbed plasma during adsorption with Staphylococcus aureus, Cancer (in press).Google Scholar
  14. Bansal, S. C., and Sjogren, H. O., 1971, Unblocking serum activity in vitro in polyoma system may correlate with antitumor effects of antiserum in vivo, Nature 233: 76.Google Scholar
  15. Bansal, S. C., and Sjogren, H. O., 1973a. Effects of BCG on various facets of the immune response against polyoma tumors in rats, Int. J. Cancer 11: 116.Google Scholar
  16. Bansal, S. C., and Sjógren, 1973b, Regression of polyoma tumors, tumor metastasis by combined unblocking and BCG treatment: Correlation with induced alterations in tumor immunity status, Int. J. Cancer 12: 179.PubMedGoogle Scholar
  17. Bansal, S. C., and Sjogren, H. O., 1974, Antitumor immune response and its manipulation in a tumor-bearing host, Isr. J. Med. Sci. 10: 939.Google Scholar
  18. Bansal, S. C., Hargraves, R., and Sjogren, H. O., 1972, Facilitation of polyoma tumor growth in rat by blocking sera and tumor eluates, Int. J. Cancer 9: 97.PubMedGoogle Scholar
  19. Bansal, S. C., Bansal, B. R., Thomas, J. L., Siegel, P. D., Rhoads, J. E., Jr., Cooper, D. R., Terman, D. S., and Mark, R., 1978, Ex vivo removal of serum IgG in a patient with colon carcinoma, Cancer 42: 1.PubMedGoogle Scholar
  20. Beisel, W. R., 1972, Pathophysiology of Staphylococcal enterotoxin, Type B (SEB) toxemia after intravenous administration to monkeys, Toxicon 10: 433.PubMedGoogle Scholar
  21. Benjamin, E., Theilen, G. H., Torten, M., Fong, S., Crow, S., and Hennes, A. M., 1978, Specific active immunotherapy (tumor vaccines) for cancer: Tumor vaccines for immunotherapy of canine lymphosarcoma, Ann. N.Y. Acad. Sci. 277: 305.Google Scholar
  22. Bennett, A., DelTacca, M., Stamford, I. F., and Zebro, T., 1977, Prostaglandins from tumors of human large bowel, Br. J. Cancer 35: 881.PubMedGoogle Scholar
  23. Bennett, A., Houghton, J. K., Lepar, D. J., and Standord, I. F., 1979, Cancer growth response to treatment and survivial time in mice: Beneficial effect of the prostaglandin synthesis inhibitor Flurbiprofen, Prostaglandins 17: 179.PubMedGoogle Scholar
  24. Bensinger, W. I., Kinet, J. P., Hennen, G., Frankenne, F., Schaus, C., Saint-Remy, M., Hoyoux, P., and Mahien, P., 1982, Plasma perfused over immobilized protein A for breast cancer, N. Engl. J. Med. 306: 935.Google Scholar
  25. Berendt, M. J., and North, R. J., 1980, T cell-mediated suppression of anti-tumor immunity: An explanation for progressive growth of an immunogenic tumor, J. Exp. Med. 151: 69.PubMedGoogle Scholar
  26. Billing, R., Minowad, J., Cline, M., Clark, B., and Lee, K., 1978, Acute lymphocyte leukemia-associated cell membrane antigen, J. Natl. Cancer Inst. 61: 423.PubMedGoogle Scholar
  27. Blasecki, J. W., and Tevethia, S. S., 1976, In vitro studies on the cellular immune response of tumor-bearing mice to SV-40 transformed cells, J. Immunol. 114: 244.Google Scholar
  28. Bleme, R. W., 1977, Circulating immune complexes in patients with breast cancer, Br. Med. J. 2: 218.Google Scholar
  29. Boder, S., 1978, Suppressor cells in the humoral immunodeficiency of multiple myeloma, Ann. Intern. Med. 88: 226.Google Scholar
  30. Bonnard, E. D., and Herberman, R. B., 1975, Suppression of lymphocyte proliferative responses by murine lymphoma cells, in: Immune Recognition ( A. Rosenthal, ed.), p. 819, Academic Press, New York.Google Scholar
  31. Borer, T., and Kallis, N., 1959, The effect of isoantibodies in vivo on three different transplantable neoplasms in mice, Cancer Res. 19: 824.Google Scholar
  32. Bottino, J. C., Rosen, R. D., Hirsh, E. M., Foster, J. B., and McBride, C. H., 1978, Response of malignant melanoma to plasma exchange surgical debulking and Corynebacterium parvum, Int. J. Artif. Organs 1: 53.PubMedGoogle Scholar
  33. Boyse, E. A., Old, L. F., and Stockert, E., 1962, Immunologic enhancement of a leukemia, Nature 194: 114.Google Scholar
  34. Brandeis, W. E., Hellson, L., Wang, Y., Good, R. A., and Day, N. K., 1978, Circulating immune complexes in sera of children with neuroblastoma: Correlation with stage of the disease, J. Clin Invest. 62: 1201.PubMedGoogle Scholar
  35. Brandeis, W. E., Tan, C., Wang, Y., Good, A., and Day, N. K., 1980, Circulating immune complexes, complement and complement component levels in childhood Hodgkin’s disease, Clin. Exp. Immunol. 39: 551.Google Scholar
  36. Broder, S., Poplack, D., Whang-Peng, J., Durm, M., Goldman, C., Muul, L., and Waldmann, T. A., 1978, Characterization of a suppressor-cell leukemia: Evidence for the requirement of an interaction of two T cells in the development of human suppressor effector cells, N. Engl. J. Med. 298: 66.Google Scholar
  37. Brooks, W. H., Netsky, M. G., Normansell, D. E., and Horwitz, D. A., 1972, Depressed cell- mediated immunity in patients with primary international tumors: Characterization of a humoral suppressive factor, J. Exp. Med. 136: 1631.PubMedGoogle Scholar
  38. Brunda, M. J., Herberman, R. B., and Holden, H. T., 1980, Inhibition of murine natural killer activity by prostaglandins, J. Immunol 124: 2682.PubMedGoogle Scholar
  39. Cantor, H., and Boyce, E., 1977, Regulation of the immune reponse by T cell subclasses, Contemp. Top. Microbiol 7: 47.Google Scholar
  40. Carnaud, C., Markowicz, O., and Trainin, N., 1974, The influence of a graft-versus-host reaction on the incidence of metastases after tumor transplantation, Cell Immunol 14: 87.PubMedGoogle Scholar
  41. Carpentier, N. A., and Miescher, A., 1983, The clinical relevance of circulating immune complexes in cancer, kidney transplantation and pregnancy, in: Immunobiology of Transplantation, Cancer and Pregnancy ( P. K. Ray, ed.), p. 375, Pergamon Press, New York.Google Scholar
  42. Carpentier, N. A., Docquier, C. E., Pugin, P., Lambert, P. H., and Miescher, A., 1978, Incidence et spécificité des complexes immune circulants dans la mononucléose infectieuse, Schweiz. Med. Wochenschr. 108: 1601.PubMedGoogle Scholar
  43. Chard, T., 1978, Immunological enhancement by mouse isoantibodies: The importance of complement fixation, Immunology 14: 383.Google Scholar
  44. Chard, T., French, M. E., and Batchelor, J. R., 1967, Enhancement of the C57 BL leukemia EL4 by fragments of isoantibodies, Transplantation 5: 1266.PubMedGoogle Scholar
  45. Chard, T., Kallis, N., Sinclair, N. R., and Cantrell, J. L., 1976, Immunologic enhancement of a murine tumor allograft by passive alloantibody IgG and F(ab), Eur. J. Immunol. 6: 38.Google Scholar
  46. Cohen, R. R., 1973, The recruitment of specific effector lymphocytes by antigen-reactive lymphocytes in cell-mediated autosensitization and allosensitization reactions, Cell Immunol 8: 209.PubMedGoogle Scholar
  47. Cohen, R. R., and Feldman, M., 1976, Suppressor factor secreted by T-lymphocytes from tumor-bearing mice, J. Natl Cancer Inst. 57: 409.PubMedGoogle Scholar
  48. Cohen, R. R., Crolberson, A., and Feldman, M., 1971, Lymphoid cells sensitized in vitro against allogeneic or syngeneic fibroblasts produce immune effects in vitro and in vivo, Transplant. Proc. 3: 891.PubMedGoogle Scholar
  49. Coley, W. B., 1891, Contribution to the knowledge of sarcoma, Ann. Surg. 14: 199.PubMedGoogle Scholar
  50. Coley, W. B., 1893, Treatment of malignant tumors by repeated inoculations of erysipelas with a report of 10 cases, Med. Res. 43: 60.Google Scholar
  51. Cooper, P. D., and Masinello, G. R., 1983, Protein A treatment of cancer: Activation of a serum component with trans-species anti-B-16 melanoma activity, Int. J. Cancer 32: 737.PubMedGoogle Scholar
  52. Costanza, M. E., Pinn, V., Schwartz, R., and Nathanson, L., 1973, Cardioembryonic antigen- antibody complexes in a patient with colonic carcinoma and nephrotic syndrome, N. Engl J. Med. 289: 520.PubMedGoogle Scholar
  53. Couser, W. B., Wagenfeld, J. B., Spargo, B. H., and Lewis, E. J., 1974, Glomerular disposition of tumor antigen in membranous nephropathy associated with colonic carcinoma, Ann. J. Med. 57: 962.Google Scholar
  54. Cowan, F. M., Klein, D. L., Armstrong, G. R., and Pearson, J. W., 1979, Neutralization of immune complex inhibition of antibody-independent cellular cytotoxicity in vitro by Staphylococcus aureus protein A, Biomedicine 30: 23.PubMedGoogle Scholar
  55. Currie, G. A., and Basham, C., 1972, Serum mediated inhibition of the immunological reactions of the patient to his own tumor: A possible role for circulating antigen, Br. J. Cancer 26: 427.PubMedGoogle Scholar
  56. Currie, G. A., and McElwain, T. J., 1975, Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: A pilot study, Br. J. Cancer 31: 143.PubMedGoogle Scholar
  57. Day, N. K., Winfield, J. G., Gee, T., Tashima, H., and Gunkle, H. G., 1976, Evidence for immune complexes involving antilymphocyte antibodies associated with hypocomple-mentemia in chronic lymphocytic leukemia, Clin. Exp. Immunol. 26: 198.Google Scholar
  58. Day, N. K., Tyler, R., Engelman, R., Harr, K., Glaser, R., Wang, C. Y., Yamamoto, J., Machida, K., Nabkas, F., Tran, X., and Good, R., 1983, Immunologic and bone marrow changes associated with remission of leukemia in cats following treatment with AMF protein A filter, Fed. Proc. 42: 5283.Google Scholar
  59. Dent, P. B., Louis, J. A., McCullock, P. B., Dunnett, C. W., and Cerottini, J. C., 1980, Correlation of elevated Clq binding activity and carcinoembryonic antigen levels with clinical features and prognosis in bronchogenic carcinoma, Cancer 45: 130.PubMedGoogle Scholar
  60. Deorger, T., 1942, The role of antibodies in immunity to transplanted leukemia in mice, J. Pathol. 54: 41.Google Scholar
  61. Diener, M., and Feldman, C., 1972, Relationship between antigen and antibody induced suppression of immunity, Transplant. Rev. 8: 76.PubMedGoogle Scholar
  62. Dore, J. G., Hadjlyannakis, M. J., and Goudert, A., 1973, Use of antigenic treated cells in immunotherapy of leukemia, Lancet 1: 600.PubMedGoogle Scholar
  63. Drebin, J. A., Waltenbaugh, C., Schatten, S., Benaceraff, B., and Greene, M. I., 1983, Inhibition of tumor growth by monoclonal anti-I-J antibodies, J. Immunol 130: 506.PubMedGoogle Scholar
  64. Eggers, A. E., and Wunderlich, K. R., 1975, Suppressor cells in tumor-bearing mice capable of nonspecific blocking of immunization against transplant antigen, J. Immunol. 114: 1554.PubMedGoogle Scholar
  65. Faltt, R., and Ankerest, J., 1980, Possibly specific immune complexes in the sera of patients with untreated acute myelogenous leukemia, Int. J. Cancer 26: 309.Google Scholar
  66. Fass, L., 1970, Patients with Burkitt’s lymphoma: Evaluation of the effect of remission plasma on untreated host, J. Natl. Cancer Inst. 44: 145.PubMedGoogle Scholar
  67. Finegold, M. J., 1967, Interstitial pulmonary edema-An electron microscopic study of the pathology of the Staphylococcal exterotoxemia in rhesus monekys, Lab. Invest. 16: 912.PubMedGoogle Scholar
  68. Frank, S. J., Specter, S., Nowotny, A., and Friedman, H., 1979, Effect of immune sera upon enhanced in vitro antibody responses, in: Macrophages and Lymphocytes: Nature, Functions, and Interaction (M. R. Escobar and H. Friedman, eds.), Advances in Experimental Medicine and Biology, Volume 121 A, p. 261, Plenum Press, New York.Google Scholar
  69. Froese, G., Berczi, I., and Sehon, A. H., 1974, Neuraminidase induced enhancement of tumor growth in mice, J. Natl. Cancer Inst. 52: 1905.PubMedGoogle Scholar
  70. Fujimoto, S., Greene, M. I., and Sehon, A. H., 1976, The nature of immunosuppressor cells in tumor-bearing hosts, J. Immunol. 116: 800.PubMedGoogle Scholar
  71. Fulton, A. M., and Levy, J. G., 1980, Inhibition of murine tumor growth and prostaglandin synthesis by indomethacin, Int. J. Cancer 26: 669.PubMedGoogle Scholar
  72. Garrett, T. J., Takahashi, T., Clarkson, B. D., and Old, L. J., 1977, Detection of antibody to autologous human leukemia cells by immune adherence assays, Proc. Natl. Acad. Sci. USA 74: 4587.PubMedGoogle Scholar
  73. Gelsner, M., Kirchner, H., Holden, H. T., and Herberman, R. B., 1976, Inhibition of cell-mediated cytotoxicity against tumor associated antigens by suppressor cells from tumor-bearing mice, J. Natl. Cancer Inst. 56: 865.Google Scholar
  74. Gershon, R. K., Birnbaum-Mokyr, M., and Mitchell, M. S., 1974, Activation of suppressor T cells by tumor cells and specific antibody, Nature 250: 594.PubMedGoogle Scholar
  75. Gifford, R. R., Boss, B. V., and Ferguson, R. M., 1981, Cimetidine protection against lethal tumor challenge in mice, Surgery 90: 344.PubMedGoogle Scholar
  76. Glaser, M., 1980, Indomethacin sensitive suppressor cells regulate the cell mediated cytotoxic response to SV 40 induced tumor associated antigens in mice, Eur. J. Immunol. 10: 489.PubMedGoogle Scholar
  77. Glaser, M., Kirchner, H., Holden, J., and Herberman, R. B., 1976, Cytotoxicity against tumor-associated antigens by suppressor cells from tumor-bearing mice, J. Natl. Cancer Inst 56: 865.PubMedGoogle Scholar
  78. Glasgow. A. H.. Nimberg, R. B., Menzoian, J. O., Inna Saporoshetz, B. A., Cooperband, S. R., Schmid, K., and Mannick, J. A., 1974, Association of anergy with an immunosuppressive peptide fraction in the serum of patients with cancer, N. Engl. J. Med. 291: 1263.PubMedGoogle Scholar
  79. Goodwin, J. S., and Cauppens, J., 1983, Regulation of the immune response by prostaglandins, J. Clin. Immunol. 3: 295.PubMedGoogle Scholar
  80. Goodwin, J. S., Messner, R. P., Bankhurst, A. D., Peake, G., Sasiki, J. H., and Williams, R. C., Jr., 1977, Prostaglandin in suppressor cells in Hodgkin’s disease, N. Engl. J. Med. 297: 963.PubMedGoogle Scholar
  81. Gorczynski, R., 1974, Immunity to murine sarcoma virus-induced tumors. II. Suppression of T cell-mediated immunity by cells from progressor animals, J. Immunol. 112: 1826.PubMedGoogle Scholar
  82. Gordon, B. R., Matus, R. E., Saal, S. D., MacEwen, G. E., Hurvitz, A. I., Stenzel, K. H., and Rubin, A. L., 1983, Protein A-independent tumoricidal responses in dogs after extracorporeal perfusion of plasma over Staphylococcus aureus, J. Natl Cancer Inst. 70: 1127.PubMedGoogle Scholar
  83. Greene, M. I., Fuzimoto, S., and Shahan, H., 1977, Regulation of the immune response to tumor antigens. III. Characterization of immunosuppressor factor produced by tumor-bearing hosts, J. Immunol 119: 757.PubMedGoogle Scholar
  84. Greenwich, K. D., and Plescia, O. J., 1977, Tumor mediated immunosuppression: Prevention by inhibitors of prostaglandin synthesis, Prostaglandins 14: 1175.Google Scholar
  85. Gupta, R. K., and Morton, D. L., 1983, Tumor antigens, in: Immunobiology of Transplantation, Cancer and Pregnancy ( P. K. Ray, ed.), p. 113, Pergamon Press, New York.Google Scholar
  86. Hamblin, T. J., 1979, Plasmapheresis and plasma exchange, Res. Rev. 1: 1.Google Scholar
  87. Heimer, R., and Kline, G., 1976, Circulating immune complexes in sera of patients with Burkitt’s lymphoma and nasopharyngeal carcinoma, Int. J. Cancer 19: 310.Google Scholar
  88. Helin, H., Pasternack, A., Hakala, T., Penttinen, K., and Wager, O., 1980, Glomerular electron-dense deposits and circulating immune complexes in patients with malignant tumours, Clin. Nephrol 14: 23.PubMedGoogle Scholar
  89. Hellstrom, I., and Hellstrom, K. E., 1969, Studies on cellular immunity and its serum mediated inhibition in Moloney virus induced mouse sarcoma, Int. J. Cancer 4: 587.PubMedGoogle Scholar
  90. Hellstrom, I., and Hellstrom, K. E., 1970, Colony inhibition studies on blocking and non-blocking serum effects on cellular immunity to Moloney sarcomas, Int. J. Cancer 4: 195.Google Scholar
  91. Hellstrom, I., Hellstrom, K. E., and Sjogren, H. O., 1970, Serum mediated inhibition of cellular immunity to methylcholanthrene induced murine sarcoma, Cell Immunol 1: 18.PubMedGoogle Scholar
  92. Hellstrom, I., Hellstrom, K. E., Sjogren, H. O., and Warner, G. A., 1971, Serum factors in tumor-free patients cancelling the blocking of cell mediated tumor immunity, Int. J. Cancer 7: 1.PubMedGoogle Scholar
  93. Hellstrom, I., Hellstrom, K. E., Warner, G. A., and Sjogren, H., 1973, Sequential studies on cell mediated immunity and blocking serum activity in 10 patients with malignant myeloma, Int. J. Cancer 11: 280.PubMedGoogle Scholar
  94. Hellstrom, K. E., 1975, The role of blocking serum factors in immunity to embryonic tumor antigens, in: Critical Factors in Cancer Immunology ( J. Schultz and R. C. Leif, eds.), p. 211, Academic Press, New York.Google Scholar
  95. Hellstrom, K. E., and Hellstrom, I., 1979, Enhancement of tumor outgrowth by tumor associated blocking factor, Int. J. Cancer 23: 366.PubMedGoogle Scholar
  96. Hellstrom, K. E., Hellstrom, I., and Nepom, P., 1977, Specific blocking factors-Are they important? Biochem. Biophys. Acta 473: 121.PubMedGoogle Scholar
  97. Herberman, R. B., 1974, Cell mediated immunity to tumor cells, Adv. Cancer Res. 19: 207.PubMedGoogle Scholar
  98. Herberman, R. B., 1977, Mechanism of tumor immunity, in: Immunotherapy of Cancer ( I. Green, S. Cohen, and R. T. McCiosky, eds.), p. 175, Wiley, New York.Google Scholar
  99. Hershey, T., Edward, A., Adam, E., Isbister, W. H., Murray, A., and Biggs, J., 1976, Antibody dependent cell mediated cytotoxicity against myeloma cells induced by plasmapheresis, Lancet 1: 825.Google Scholar
  100. Hewitt, H. B., 1978, The choice of animal tumors for experimental studies of cancer therapy, Adv. Cancer Res. 27: 149.PubMedGoogle Scholar
  101. Hewitt, H. B., Blake, E. R., and Walder, A. S., 1976, A critique of the evidence for active host defence against cancer based on personal studies of 27 murine tumors of spontaneous origin, Br. J. Cancer 33: 241.PubMedGoogle Scholar
  102. Hial, B., Horokova, A., Shaff, R. E., and Beven, M. A., 1976, Alteration of tumor growth by aspirin and indomethacin: Studies with 2 transplantable tumors in mice, Can. J. Pharmacol. 37: 367.Google Scholar
  103. Hodes, R. J., Nadler, L. M., and Hathcock, S., 1977, Regulatory mechanisms in cell mediated immune response. III. Antigen specific and nonspecific suppressor activities generated during MLC, J. Immunol. 119: 961.PubMedGoogle Scholar
  104. Hodoval, L. F., Morris, E. L., Crawley, G. J., and Beisel, W. R., 1968, Pathogenesis of lethal shock after intravenous Staphylococcal enterotoxin B in monkeys, Appl. Microbiol 19: 187.Google Scholar
  105. Hollander, N., Isakov, N., Segal, S., and Feldman, M., 1978, Immunoregulatory factor associated with spleen cells from tumor-bearing animals. II. Characterization of the cell population involved in its production and release, Int. J. Cancer 22: 471.PubMedGoogle Scholar
  106. Holohan, T. V., Phillips, T. M., Bowles, C., and Deisseroth, A., 1982, Regression of canine mammary carcinoma after immunoadsorption therapy, Cancer Res. 42: 3663.PubMedGoogle Scholar
  107. Hubert, R. A., Aggio, M. C., Lozzio, B. B., and Wust, C. J., 1981, Relation of circulating immune complexes and disease status in patients with leukemia, Clin. Exp. Immunol. 43: 46.Google Scholar
  108. Hutchin, P., Amos, D. B., and Prioleau, W. H., Jr., 1967, Interaction of humoral antibody and immune lymphocytes, Transplantation 4: 68.Google Scholar
  109. Isakov, N., Segal, S., Hollander, N., and Feldman, M., 1978, Immunoregulatory factor associated with spleen cells from tumor-bearing animals. I. Effect on tumor growth and antibody production, Int. J. Cancer 22: 465.PubMedGoogle Scholar
  110. Isakov, N., Hollander, N., Segal, S., and Feldman, M., 1979, Immunoregulatory factor associated with spleen cells from tumor-bearing animals. III. Characterization of the factor’s target cell. Int. J. Cancer 23: 410.PubMedGoogle Scholar
  111. Isbister. W. H., Noona, F. P., Halliday, W. J., and Clunie, G., 1975, Human thoracic duct cannulation: Manipulation of tumor-specific blocking factors in a patient with malignant melanoma, Cancer 35: 145.Google Scholar
  112. Israel, L., Edelstein, R., Mannoni, P., Rodot, E., and Greenspan, E. M., 1977, Plasmapheresis in patients with disseminated cancer: Clinical results and correlations with changes in serum protein. The concept of nonspecific blocking factors, Cancer 40: 3146.PubMedGoogle Scholar
  113. Jones, F. R., Yoshida, L. H., Ladiges, W. C., and Kennedy, M. A., 1980, Treatment of feline leukemia and reversal of FeLV by ex vivo removal of IgG: A preliminary report, Cancer 46: 675.PubMedGoogle Scholar
  114. Jose, D. G., and Sashadri, R., 1974, Circulating immune complexes in human urogastroma: Direct assay and role in blocking specific cellular immunity, Int. J. Cancer 13: 824.PubMedGoogle Scholar
  115. Kamo, I., and Freidman, H., 1977, Immunosuppression and the role of suppressive factors in cancer, Adv. Cancer Res. 25: 271.PubMedGoogle Scholar
  116. Kerbal, R. S., and Pears, A. J. S., 1974, The possible biological significance of Fc receptors on mammalian lymphocytes and tumor cells, Cell 3: 105.Google Scholar
  117. Kilburn, D. G., Smith, J. B., and Gorczynsky, R. M., 1974, Nonspecific suppression of T lymphocyte responses in mice carrying progressively-growing tumors, Eur. J. Immunol. 4: 784.Google Scholar
  118. Kiley, J. M., Wagoner, R. G., and Holley, K. E., 1969, Renal complications of lymphoma, Ann. Intern. Med. 71: 1159.Google Scholar
  119. Kirchner, H., Chused, T. M., and Herberman, R. B., 1974, Evidence of suppressor cell activity in spleens of mice bearing primary tumors induced by Moloney sarcoma virus, J. Exp. Med. 139: 1473.PubMedGoogle Scholar
  120. Klein, E., 1977, Tumor immunology escape mechanism, Ann. Inst. Pasteur 122: 593.Google Scholar
  121. Klimpal, G. R., 1980, A soluble factor for BCG induced suppressor cells inhibits in vitro PFC responses but not cytotoxic response, Cell. Immunol. 47: 218.Google Scholar
  122. Klimpal, G. R., Idada, M., and Henney, C. S., 1979, Inhibition of in vitro cytotoxic responses by BCG induced macrophage-like suppressor cells. II. Suppression occurs at the level of a “helper” T cell, J. Immunol 123: 350.Google Scholar
  123. Kline, B. C., and Raisz, L. G., 1970, Prostaglandins: Stimulation of bone resorption in tissue culture, Endocrinology 86: 1436.Google Scholar
  124. Kumar, V., and Bennett, M., 1977, H-2 compatibility requirements for T-suppressor cell functions induced by Friend leukaemia virus, Nature 265: 345.PubMedGoogle Scholar
  125. Kuperman, O., Fortner, G. W., and Lucas, Z. J., 1975, Immune response to a syngeneic mammary adenocarcinoma. III. Development of memory and suppressor functions modulating cellular cytotoxicity, J. Immunol. 115: 1282.PubMedGoogle Scholar
  126. Langford, M. P., Stanton, G. J., and Johnson, H. M., 1978, Biological effects of Staphylococcal enterotoxin A on human peripheral lymphocytes, Infect. Immun. 22: 62.PubMedGoogle Scholar
  127. Langone, J. J., Boyle, M. D. P., and Borsos, T., 1978, Studies on the intersection between protein A and immunoglobulin G. II. Composition and activity of complexes formed between protein A and IgG, J. Immunol 121: 333.PubMedGoogle Scholar
  128. Langvade, E., Hyden, H., Wolf, H., and Kroeigard, N., 1975, Extracorporeal immunoadsorption of circulating specific serum factors in cancer patients, Br. J. Cancer 32: 680.Google Scholar
  129. Lee, J. C., Yamachui, H., and Hopper, S., Jr., 1963, The association of cancer and the nephrotic syndrome, Ann Int. Med. 64: 41.Google Scholar
  130. Linder, E., 1981, Binding of Clq and complement activation by vascular endothelium, J. Immunol 126: 648.PubMedGoogle Scholar
  131. Lockwood, C. M., Worlledge, S., Nicholas, A., Cotton, C., and Peters, D. K., 1979, Reversal of impaired splenic function in patients with nephritis or vasculitis (or both) by plasma exchange, N. Engl. J. Med. 300: 524.PubMedGoogle Scholar
  132. Long, K. C., Hall, C. L., Brown, C. A., Stamatos, C., Weitzman, S. A., and Carey, E. K., 1977, Binding of soluble immune complexes in serum of patients with Hodgkin’s disease to tissue cultures derived from the tumor, N. Engl. J. Med. 297: 295.PubMedGoogle Scholar
  133. Lynch, N. R., Casatel, M., Estonim, M., and Solmen, J. C., 1978, Mechanism of inhibition of tumor growth by aspirin and indomethacin, Br. J. Cancer 38: 305.Google Scholar
  134. McCredie, J. A., Brown, E. R., and Cole, W. H., 1959, Immunological treatment of tumors, Proc. Soc. Exp. Biol. Med. 100: 31.PubMedGoogle Scholar
  135. McKenzie, P. E., Taylor, A. E., Woodruff, A. J., Seymour, A. E., Chang, Y. L., and Clarkson, A. L., 1979, Plasmapheresis in glomerular nephritis, Clin. Nephrol 12: 97.PubMedGoogle Scholar
  136. MacKintosh, F. R., Bennett, K., Schiff, S., Shield, J., and Hall, S. W., 1983, Treatment of advanced malignancy with plasma perfused over Staphylococcal protein A, West. J. Med. 139: 36.PubMedGoogle Scholar
  137. Martin, D., Achard, A., Todd, D. E., Tribole, T., Lewis, J. A., and Zander, E., 1980, Immune complexes associated with brain tumors: Correlation with prognosis, Surg. Neurol 13: 161.Google Scholar
  138. Martin, F., and Martin, S. M., 1970, Demonstration of antigens related to colonic cancer in human digestive system, Int. J. Cancer 6: 362.Google Scholar
  139. Mathe, G., Hale-Pannenko, O., and Bourut, C., 1973, Active immunotherapy in spontaneous leukemia of AKR mice, Exp. Hematol. 1: 110.PubMedGoogle Scholar
  140. Messerschmidt, G., Bowles, C., Alsaker, R., McCormick, K., and Deiseroth, A., 1982, Toxic, immunologic and pathologic changes in dogs with spontaneous neoplasia treated with i. v. infusions of purified staph protein A (spA), Fed. Proc. 41: 325.Google Scholar
  141. Mills, C. C., North, R. J., and Dye, E. S., 1981, Mechanism of antitumor action of Coryne-bacterium parvum. II. Potentiated cytolytic T cell response and its tumor-induced suppression, J. Exp. Med. 154: 621.PubMedGoogle Scholar
  142. Mizushima, Y., Sendo, F., Takeichi, N., Hosohawa, M., and Kobayashi, H., 1981, Enhancement of anti-tumor transplantation resistance in rats by appropriately timed administration of Busulfan, Cancer Res. 41: 2917.PubMedGoogle Scholar
  143. Möller, E., and Möller, G., 1962, Quantitative studies of the sensitivity of normal and neoplastic mouse cells to the cytotoxic action of isoantibodies, J. Exp. Med. 115: 527.PubMedGoogle Scholar
  144. Möller, G., 1963, Studies on the mechanism of immunological enhancement of tumor homografts. II. Effect of isoantibodies on various tumor cells. J. Natl. Cancer Inst. 30: 1177.PubMedGoogle Scholar
  145. Möller, G., 1964, Effect on tumor growth in syngeneic recipients of antibodies against tumor specific antigens in methylcholanthrene induced mouse sarcomas, Nature 204: 846.PubMedGoogle Scholar
  146. Montovanni, A., and Soraflco, F., 1975, On the nature of blocking factors and their lymphoid target cells in an alogeneic tumor system, Eur. J. Cancer 11: 451.Google Scholar
  147. Moore, A. E., and Gerner, R. E., 1970, Cancer immunity hypothesis and clinical trial of lymphocyte therapy for malignant diseases, Ann. Surg. 172: 733.PubMedGoogle Scholar
  148. Moore, G., Scandberg, A., and Amos, D. B., 1957, Experimental and clinical adventures with large doses of gamma and other globulins as anticancer agents, Surgery 41: 972.PubMedGoogle Scholar
  149. Noar, D., 1979, Suppressor cells: Parameters and promoters of malignancy, Adv. Cancer Res. 29: 45.Google Scholar
  150. Nata, R., and Slavin, S. B., 1979, Endurance in the induction of suppressor cells, Infect. Immun. 23: 360.Google Scholar
  151. Nelson, D. S., 1973, Production of stimulated macrophages of factors depressing lymphocyte transformation, Nature 246: 306.PubMedGoogle Scholar
  152. Nimberg, R. B., Glasgow, J. H., Menzoian, J. O., Constantine, M. B., Cooperband, S. R., Mannick, J. A., and Schmid, K., 1975, Isolation of a γ immunosupressive type fraction from the serum of cancer patients, Cancer Res. 35: 1489.PubMedGoogle Scholar
  153. Noonan, P. F., Gasdrin, M. A. H., Clunie, G. J., Isbister, W. H., and Halliday, W. J., 1974, Control of tumor growth in mice by thoracic duct drainage: Relationship to blocking factor in lymph, Int. J. Cancer 13: 640.PubMedGoogle Scholar
  154. Oehler, J. R., Herberman, R. B., Campbell, D. A. J., and Jeu, J. Y., 1977, Inhibition of rat mixed lymphocyte cultures by suppressor macrophages, Cell. Immunol. 29: 238.PubMedGoogle Scholar
  155. Old, L. J., and Boyse, E. A., 1964, Immunology of experimental tumors, Annu. Rev. Med. 15: 167.PubMedGoogle Scholar
  156. Old, L. J., and Stockert, E., 1977, Immunogenetics of cell surface antigens of mouse leukemia, Annu. Rev. Genet. 11: 1.Google Scholar
  157. Oldston, M. B., and Tishow, A., 1977, Active thymus derived lymphocytes in human cord blood, Nature 269: 333.Google Scholar
  158. Oldston, M. B., Theofilopoulus, A. N., Kline, G., and Guvin, T., 1975, Immune complexes associated with neoplasia: Presence of Epstein-Barr virus antigen-antibody complexes in Burkitt’s lymphoma, Intervirology 4: 292.Google Scholar
  159. Opitz, H. G., Niethammer, D., Jackson, R. D., Lemke, H., Huget, R., and Glad, H. G., 1975a, Biochemical characterization of a factor released by macrophages, Cell. Immunol. 18: 70.PubMedGoogle Scholar
  160. Optiz, H. G., Niethammer, D., Lemke, H., Glad, H. D., and Huget, R., 1975b, Inhibition of tritiated thymidine incorporation of lymphocytes by a soluble factor from macrophages, Cell. Immunol. 16: 379.Google Scholar
  161. Padrathsingh, M. L., Dean, J. H., and Jarrell, T. R., 1979, Evidence for and characterization of suppressor cells in Balb/C mice bearing ADJ/TC 5 plasmacytoma, J. Natl Cancer Inst. 61: 1235.Google Scholar
  162. Pascal, R. R., Ianaconne, P. N., Rollwagen, F. M., Harding, T. A., and Bennett, S. J., 1976, Electron microscopy and immunofluorescence of glomerular immune complex deposits in cancer patients, Cancer Res. 36: 43.PubMedGoogle Scholar
  163. Peavy, D. L., Adler, W. H., and Smith, R. T., 1970, The mitogenic effects of endotoxin and Staphylococcal enterotoxin B on mouse spleen cells and human peripheral lymphocytes, J. Immunol. 105: 1453.PubMedGoogle Scholar
  164. Pelus, C., and Backman, R., 1979, Increased prostaglandin synthesis by macrophages from tumor-bearing mice, J. Immunol. 123: 1979.Google Scholar
  165. Perry, L. L., Benacerraf, B., and Greene, M. L., 1978, Regulation of the immune response to tumor antigens. IV. Tumor antigen specific suppressor factors: Their IJ determinants and induced suppressor T cells in vivo, J. Immunol 121: 2144.PubMedGoogle Scholar
  166. Peter, J. J., Pavie-Fischer, D., Fridman, W. H., Aubert, C., Cesarini, J. P., Roubin, R., and Kourilsky, F., 1975, Cell mediated cytotoxicity in vitro of human lymphocytes against a tissue culture animal cell line (IG R3), J. Immunol 115: 539.PubMedGoogle Scholar
  167. Philips, M., and Stetson, C., 1962, Basic transfer of immunity to sarcoma I with serum, Proc. Soc. Exp. Biol Med. 111: 265.Google Scholar
  168. Pickett, S. H., Reichert, D. F., Lucio, R. M., and Lamm, D. L., 1983, Staphylococcus protein A immunotherapy of transitional cell carcinoma, Fed. Proc. 42: 3197.Google Scholar
  169. Pierce, G. E., 1971, Enhanced growth of primary Moloney virus induced sarcoma in mice, Int. J. Cancer 8: 22.PubMedGoogle Scholar
  170. Plescia, O. J., Smith, A. H., and Greenwich, K., 1975, Suppression of immune system by tumor cells and role of prostaglandins, Proc. Natl Acad. Sci. 72: 1848.PubMedGoogle Scholar
  171. Pollard, M., and Luckert, H., 1981, Effect of indomethacin on intestinal tumors induced in rats by the acetate derivative of dimethyl nitrosamine, Science 214: 558.PubMedGoogle Scholar
  172. Pope, B. L., Witney, R. B., Levy, J. G., and Kilburn, D. G., 1976, Suppressor cells in the spleens of tumor-bearing mice: Enrichment by centrifugation on hypaque-Ficoll and characterization of the suppressor population, J. Immunol 116: 1342.PubMedGoogle Scholar
  173. Poulton, T. A., Crowther, M. E., Hay, F. C., and Nineheim, M. J., 1978, Immune complexes in ovarian cancer, Lancet 2: 72.PubMedGoogle Scholar
  174. Poupon, M. F., Kolb, J. P., and Lespinats, G., 1976, Evidence of suppressor cells in C3H/ HEJ T cell deprived and nude mice bearing a 3-methylcholanthrene induced fibrosarcoma, J. Natl Cancer Inst. 57: 1241.PubMedGoogle Scholar
  175. Prehn, R. T., 1976, Tumor progression and homeostasis, Adv. Cancer Res. 23: 203.PubMedGoogle Scholar
  176. Proctor, J. W., Rudenstam, C. M., and Alexander, P., 1973, A factor preventing development of lung metastases in rats with sarcoma, Nature 242: 29.PubMedGoogle Scholar
  177. Purves, L., and Geddes, E., 1972, Proceedings, symposium on mycotoxin in human health, Lancet 1: 47.PubMedGoogle Scholar
  178. Ray, P. K., 1981, L’adsorption ex vivo d’immunoglobulines pathologiques ou de complexes immuns: Est-elle a preferer a Fechange de plasma? Med. Hyg. 39: 1737.Google Scholar
  179. Ray, P. K., 1982, Suppressor control as a modality of cancer treatment: perspectives and prospects in the immunotherapy of malignant disease, Plasma Ther. Transfusion Technol. 3: 101.Google Scholar
  180. Ray, P. K., 1983, Extracoproreal adsorption of pathologic gammaglobulins and immune complexes in various diseases including cancer, Plasma Ther. Transfusion Technol 4: 289.Google Scholar
  181. Ray, P. K., and Bandyopadhyay, S., 1983, Inhibition of rat mammary tumor growth by purified protein A-A potential anti-tumor agent. Immunol. Commun. 12: 453.PubMedGoogle Scholar
  182. Ray, P. K., and Raychaudhuri, S., 1981, Low-dose cyclophosphamide inhibition of tumor growth by augmenting the immume response of the host, J. Natl. Cancer Inst. 67: 1341.PubMedGoogle Scholar
  183. Ray, P. K., and Raychaudhuri, S., 1983, Immunotherapy of cancer—Present status and future trends in: Immunobiology of Transplantation, Cancer and Pregnancy (P. K. Ray, ed.), p. 210, Pergamon Press, New York.Google Scholar
  184. Ray, P. K., and Raychaudhuri, S., 1985, Increasing concentration of polyethylene glycol precipitable immune complexes during progressive tumor growth, Eur. J. Cancer (in press).Google Scholar
  185. Ray, P. K., and Saha, S., 1982, Changes in elution profile of plasma proteins from mice with progressive methycholanthrene fibrosarcoma on Sephadex G-200 column, Proc. Am. Assoc. Cancer Res. 73: 978.Google Scholar
  186. Ray, P. K., and Saha, S., 1985a, Tumor antigen induced generation of humoral and cellular suppressor factors, Ind. J. Exp. Biol, (in press).Google Scholar
  187. Ray, P. K., and Saha, S., 1985b, Isolation of tumor specific antigen from plasma of mice carrying methycholanthrene-induced fibrosarcomas, J. Immunol. Methods (in press).Google Scholar
  188. Ray, P. K., and Seshadri, M., 1980, Effect of immunization of mice with syngeneic embryos on their ability to inhibit the growth of a challenging fibrosarcoma, Ind. J. Exp. Biol 18: 1027.Google Scholar
  189. Ray, P. K., and Seshadri, M., 1981, Influence of parity status of female mice on growth of a transplantable chemically-induced fibrosarcoma, Ind. J. Exp. Biol. 19: 404.Google Scholar
  190. Ray, P. K., Idiculla, A., Rhoads, J. E., Jr., Mark, R., Besa, E., Thomas, H., Bassett, J. G., and Cooper, D. R., 1979c, Extracorporeal immunoadsorption of pathologic plasma immunoglobulin G and its complexes: A novel approach for the selective removal from the plasma, in: First Annual Plasmapheresis Symposium: Current Topics and Future Trends, p. 203, American Red Cross, Mid-America Region, Chicago.Google Scholar
  191. Ray, P. K., Cooper, D. R., Bassett, J. G., and Mark, R., 1979b, Antitumor effect of Staphylococcus aureus organisms, Fed. Proc. 38: 4558.Google Scholar
  192. Ray, P. K., Idiculla, A., Besa, E., Bassett, J. G., and Cooper, D. R., 1980c, Immunoadsorption of IgG molecules of the plasma of multiple myeloma and autoimmune hemolytic anemia patients, Plasma Ther. Transfusion Technol. 1: 11.Google Scholar
  193. Ray, P. K., De, B. K., and Guha, S., 1980b, Facilitation and/or inhibition of growth of sarcoma 190 ascites tumor by BCG: Effect of BCG on tumor cell membrane, Ind. J. Exp. Biol. 18: 123.Google Scholar
  194. Ray, P. K., Idiculla, A., Rhoads, J. E., Jr., Bassett, J. G., and Cooper, D. R., 1980c, Immunoadsorption of blocking immune complexes using protein A column—A novel approach for immunotherapy of cancer, Fourth Int. Cong. Immunol. 10: 5.Google Scholar
  195. Ray, P. K., Besa, E., Idiculla, A., Rhoads, J. E., Jr., Bassett, J. G., and Cooper, D. R., 1980d, Extracorporeal immunoadsorption of myeloma IgG and autoimmune antibodies: A clinically feasible modality of treatment, Clin. Exp. Immunol. 42: 308.PubMedGoogle Scholar
  196. Ray, P. K., Besa, E., Idiculla, A., Rhoads, J. E., Jr., Bassett, J. G., and Cooper, D. R., 1980e, Efficient removal of immunoglobulin G from the plasma of a multiple myeloma patient-Description of a new method for treatment of hyperviscosity syndrome, Cancer 45: 263.Google Scholar
  197. Ray, P. K., Idiculla, A., Rhoads, J. E., Jr., Bassett, J. G., and Cooper, D. R., 1980f, Extracorporeal immunoadsorption using protein A-containing Staphylococcus aureus column: A method for the quick removal of abnormal IgG and/or its complexes from the plasma, in: Plasma Exchange Therapy, International Symposium ( H. Borberg and P. Reuther, eds.), p. 150, Karger, Basel.Google Scholar
  198. Ray, P. K., McLaughlin, D., Mohammed, J., Idiculla, A., Rhoads, J. E., Jr., Mark, R., Bassett, J. G., and Cooper, D. R., 1981c, Ex vivo immunoadsorption of IgG or its complexes- A new modality of cancer treatment, in: Immune Complexes and Plasma Exchanges in Cancer Patients (B. Serrou and C. Rosenfeld, eds.), p. 197, Elsevier/North-Holland, Amsterdam.Google Scholar
  199. Ray, P. K., Idiculla, A., Clark, A., Clarke, L., Rhoads, J. E., Jr., Bassett, J. G., and Cooper, D. R., 1981b, Immunoadsorption of plasma IgG and or its complexes from colon carcinoma patients-An adjunct therapy for cancer, in: Third International Conference on Adjuvant Therapy, University of Arizona, Tucson, Arizona, p. 29.Google Scholar
  200. Ray, P. K., Raychaudhuri, S., McLaughlin, D., Idiculla, A., Rhoads, J. E., Jr., and Bassett, J. G., 1981c, Ability of nonviable Staphylococcus aureus Cowan I to bind ionized calcium in in vitro and ex vivo perfusion systems, Cancer Res. 41: 5010.PubMedGoogle Scholar
  201. Ray, P. K., Idiculla, A., Mark, R., Rhoads, J. E., Jr., Thomas H., Bassett, J. G., and Cooper, D. R., 1982a, Extracorporeal immunoadsorption of plasma from a metastatic colon carcinoma patient by protein A-containing nonviable Staphylococcus aureus, Cancer 49: 1800.PubMedGoogle Scholar
  202. Ray, P. K., Raychaudhuri, S., and Allen, P., 1982b, Mechanism of regression of mammary adenocarcinomas in rats following plasma absorption over protein A—containing Staphylococcus aureus, Cancer Res. 42: 4970.PubMedGoogle Scholar
  203. Ray, P. K., Mohammed, J., Allen, P., Raychaudhuri, S., Dohadwala, M., Bandyopadhyay, S., and Mark, R., 1984a, Effect of frequency of plasma adsorption over protein A-containing Staphylococcus aureus on regression of rat mammary adenocarcinomas: Modification of antitumor immune response and tumor histopathology, J. Biol Resp. Modif. 3: 39.Google Scholar
  204. Ray, P. K., McLaughlin, D., Allen, P., Bandyopadhyay, S., Idiculla, A., Clarke, L., Mark, R., Rhoads, J. E., Jr., Bassett, J. G., and Cooper, D. R., 1984b, Plasma adsorption of tumor- bearing hosts with protein A containing nonviable Staphylococcus aureus Cowan I- therapeutic implications and possible mechanisms, J. Biol Resp. Modif. 3: 293.Google Scholar
  205. Ray, P. K., Bandyopadhyay, S., Dohadwala, M., Canchanapan, P., and Mobini, J., 1984c, Antitumor activity with non-toxic doses of protein A, Cancer Immunol. Immunother. 18: 29.PubMedGoogle Scholar
  206. Raychaudhuri, S., Ray, P. K., Bassett, J. G., and Cooper, D. R., 1980, High dose antigen induced suppressor generation in normal and tumor-bearing hosts, Fed. Proc. 39: 696.Google Scholar
  207. Renacle-Bonnett, M. M., Pommier, G. J., Ranee, R. J., and Depieds, R. C., 1978, Nonspecific suppressor and cytostatic activities mediated by human colonic carcinoma tissue on cultured extract, J. Immunol. 121: 44.Google Scholar
  208. Rodey, G. E., Spreader, J. C., and Bortin, M. M., 1974, Inhibition of normal allogeneic responder cells in mouse mixed leukocyte culture by long passage AKR leukemic lymphoblasts, Cancer Res. 34: 1289.PubMedGoogle Scholar
  209. Roland, P. H., Martin, P. M., Jacquemier, J., Rolland, A. M., and Toga, M., 1980, Prostaglandin in human breast cancer: Evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells, J. Natl. Cancer Inst. 64: 1061.Google Scholar
  210. Ron, M., and Witz, I. P., 1972, Tumor associated immunoglobulins: Enhancement of syngeneic tumors by IgG2-containing eluates, Int. J. Cancer 9: 242.Google Scholar
  211. Rossen, R. D., and Morgan, A. C., 1981, Blockage of the humoral immune response: Immune complexes in cancer, in: The Handbook of Cancer Immunology, Vol. 9 ( H. Walters, ed.), p. 209, Garland STM Press, New York.Google Scholar
  212. Rossen, R. D., Reisberg, M., Hersh, E. M., and Gutterman, J. V., 1977, The Clq binding test for soluble immune complexes: Clinical correlation obtained in patients with cancer, J. Natl. Cancer Inst. 58: 1205.PubMedGoogle Scholar
  213. Rosenberg, S. A., and Perry, W. B., 1977, Passive immunotherapy of cancer in animals and man,, Adv. Cancer Res. 25: 323.PubMedGoogle Scholar
  214. Rotter, V., and Trainin, N., 1975, Inhibition of tumor growth in syngeneic chimeric mice mediated by a depletion of suppressor T cells, Transplantation 20: 68.PubMedGoogle Scholar
  215. Rubenstein, P., Decary, R., and Strum, E. W., 1974, Quantitative studies on tumor enhancement in mice. I. Enhancement of Sal induced IgM, IgG1 and IgG2, J. Exp. Med. 140: 591.Google Scholar
  216. Saha, S., and Ray, P. K., 1982, Regulatory role of tumor antigen in the generation of humoral and cellular tumor growth enhancing factors in mice, Fed. Am. Soc. Exp. Biol. 41: 411.Google Scholar
  217. Salinas, F. A., Silver, H. K. B., Grossman, L., and Thomas, J. W., 1981, Plasmapheresis: A new approach in the management of advanced malignant melanoma, in: Immune Complexes and Plasma Exchanges in Cancer Patients ( B. Serrou and C. Rosenfeld, eds.), p. 253, Elsevier/North-Holland, Amsterdam.Google Scholar
  218. Salinas, F. A., and Wee, K. H., 1983, Immune complexes and human neoplasia. I., Biomed. Pharmacother. 36: 119.Google Scholar
  219. Samayoa, E. H., McDuffie, F. C., Nelson, A. M., Go, V. L. Luthar, H. S., and Brumfield, H. N., 1977, Immunoglobulin complexes in sera of patients with malignancy, Int. J. Cancer 19: 12.PubMedGoogle Scholar
  220. Savary, C. A., and Lotova, 1978, Suppression of natural killer cell cytotoxicity by splenocytes from Corynebacterium parvum injected bone marrow tolerant and infant mice, J. Immunol 120: 239.PubMedGoogle Scholar
  221. Sengupta, J., and Ray, P. K., 1979, Sharing of antigens between sarcoma 180 tumors and mouse embryos, Fed. Am. Soc. Exp. Biol 38: 5857.Google Scholar
  222. Serrou, B., Cupisol, D., and Caraux, J., 1980, Ability of thymosin to decrease in vivo and in vitro suppressor cell activity in tumor-bearing mice and cancer patients, Recent Results Cancer Res. 75: 110.PubMedGoogle Scholar
  223. Sjogren, H. O., Hellstrom, I., Bansal, S. C., and Hellstrom, K. E., 1971, Suggestive evidence that blocking antibodies of tumor-bearing hosts may be antigen-antibody complexes, Proc. Natl Acad. Sci. USA 68: 1372.PubMedGoogle Scholar
  224. Small, M., 1977, Characterization of the immature cells involved in T cell mediated enhancement of syngeneic tumor, J. Immunol 118: 1517.PubMedGoogle Scholar
  225. Smith, E. M., Johnson, H. M., and Blaylock, J. E., 1983, Staphylococcus aureus protein A induces the production of interferon-γ in human lymphocytes and interferon-α in mouse spleen cells, J. Immunol 130: 773.PubMedGoogle Scholar
  226. Sparks, F. C., and Breeding, J. H., 1974, Tumor regression and enhancement resulting from immunotherapy with Bacillus Calmette-Guerin and neuraminidase, Cancer Res. 34: 3262.PubMedGoogle Scholar
  227. Spence, R. J., Simon, R. M., and Baker, A. R., 1978, Failure of immunotherapy with neuraminidase treated tumor cell vaccine in mice bearing established 3-methylcholanthrene induced sarcomas, J. Natl Cancer Inst. 60: 451.PubMedGoogle Scholar
  228. Staab, H. J., Anderer, F. A., Stump, F. E., and Fischer, R., 1980, Are circulating immune complexes a prognostic marker in patients with carcinoma of the gastrointestinal tract? Br. J. Cancer 42: 26.PubMedGoogle Scholar
  229. Steele, G., Ankerest, J., and Sjogren, H. O., 1974, Alteration of in vitro antitumor activity of tumor bearers’ sera by adsorption with Staphylococcus aureus Cowan I, Int. J. Cancer 14: 83.PubMedGoogle Scholar
  230. Stein, P. C., Christiansen, N., and Char, D. H., 1980, Characterization of retinoblastoma immune complexes, Invest. Ophthalmol Verseral Sci. 19: 302.Google Scholar
  231. Stelzer, G. T., and Wallace, J. H., 1977, Suppressor cells in mice bearing the B-16 melanoma, Proc. Am. Assoc. Cancer Res. 18: 68.Google Scholar
  232. Stevens, R. H., Brooks, G. P., Osborn, J. W., Hoffman, K. L., and Lawson, A. J., 1978, Lymphocyte cytotoxicity in X irradiation induced rat small bowel adenocarcinoma III: Blocking by 3 M KC1 extract, J. Immunol 12: 335.Google Scholar
  233. Strausser, H. R., and Humes, J. L., 1975, Prostaglandin synthesis inhibition: Effect on bone changes and sarcoma tumor induction in mice, Int. J. Cancer 15: 724.PubMedGoogle Scholar
  234. Suckalova, A., Gazzola, S., Hrubisko, M., and Slakova, J., 1973, Clinical utilization of plasmapheresis and cyclophosphamide in the treatment of malignant lymphoproliferated processes, Neoplasma 20: 335.Google Scholar
  235. Sulica, A., Kaly, M., Gherman, M., Ghetie, V., and Sjoquist, J., 1976, Arming of lymphoid cells by IgG antibodies treated with protein A from Staphylococcus aureus, Scand. J. Immunol 5: 1191.PubMedGoogle Scholar
  236. Tada, T., Taniguchi, M., and Takemori, T., 1975, Properties of primed suppressor T cells and their products, Transplant. Rev. 26: 106.PubMedGoogle Scholar
  237. Takei, F., Levy, J. G., and Kilburn, B. G., 1976. In vitro induction of cytotoxicity against syngeneic mastocytoma and its suppression by spleen and thymus cells from tumorbearing mice, J. Immunol. 116: 288.PubMedGoogle Scholar
  238. Tanaguchi, M., Hayaka, W. A., and Tada, T., 1976, Properties of antigen-specific suppressor T cell factor in the regulation of antibody response of the mouse. II. In vitro activity and evidence for the I region gene product, J. Immunol 116: 542.Google Scholar
  239. Tashjain, A. H., Voekel, E. F., Levine, L., and Goldhaber, P., 1972, Evidence that the bone resorption stimulator factor produced by mouse fibrosarcoma cells is prostaglandin, J. Exp. Med. 136: 1329.Google Scholar
  240. Terman, D. S., Yamamoto, T., Tillquist, R. L., Cook, G., Silvers, A., and Shearer, W. T., 1980a, Tumoricidal response induced by cytosine arabinoside after plasma perfusion over protein A, Science 209: 1257.PubMedGoogle Scholar
  241. Terman, D. S., Yamamoto, T. Mattioli, M., Cook, G., Tillquist, R., Henry, J., Poser, R., and Daskal, Y., 1980b, Extensive necrosis of spontaneous canine mammary adenocarcinoma after extracorporeal perfusion over Staphylococcus aureus Cowan I. I. Description of acute tumoricidal response, morphologic, histologic, immunohistochemical, immunologic and serologic findings, J. Immunol 124: 795.PubMedGoogle Scholar
  242. Terman, D. S., Young, J. B., Shearer, W. T., Ayus, C., Mattioli, C., Lehane, D., Espada, R., Howell, J. F., Yamamoto, T., Zeleski, H. I., Henry, J. F., Feldman, L., Miller, L., Frommer, P., Tillquist, R., Cook, G., and Daskal, Y., 1981, Preliminary observations of the effects on breast carcinoma of plasma perfused over immobilized protein A, N. Engl J. Med. 305: 1195.PubMedGoogle Scholar
  243. Teshima, H., Wanebo, H., Pinsky, C., and Day, N. K., 1977, Circulating immune complexes detected by 125I-Clq deviation test in sera of cancer patients, J. Clin. Invest. 59: 1134.PubMedGoogle Scholar
  244. Theofilopoulos, A. N., Wilson, C. B., and Dixon, F. J., 1976, The Raji cell radioimmunoassay for detecting immune complexes in human sera, J. Clin. Invest. 57: 169.PubMedGoogle Scholar
  245. Theofilopoulos, A. N., Andrews, B. S., Urist, M. M., Morton, D. L., and Dixon, F. J., 1977, The nature of immune complexes in human cancer sera, J. Immunol 119: 657.PubMedGoogle Scholar
  246. Thomas, D. W., Rover, W. K., and Talmage, D. W., 1975, Regulation of the immune responses: Production of a soluble suppressor by immune cells, J. Immunol 114: 1616.PubMedGoogle Scholar
  247. Tilkin, A. F., Schaff-Lafontaine, N., Vanker, A. C., Boccadoro, M., and Urbain, J., 1981, Reduced tumor growth after low-dose irradiation or immunization against blastic suppressor T cells, Proc. Natl Acad. Sci. USA 78: 1809.PubMedGoogle Scholar
  248. Treves, A. J., Carnaud, C., and Trainin, N., 1974, Enhancing T lymphocytes from tumor- bearing mice suppressed host resistance to a syngeneic tumor, Eur. J. Immunol 4: 722.PubMedGoogle Scholar
  249. Treves, A. J., Cohen, I. R., and Feldman, M., 1976, Suppressor factor secreted by T-lymphocytes from tumor-bearing mice, J. Natl Cancer Inst. 57: 409.PubMedGoogle Scholar
  250. Turk, J. L., Parker, D., and Poulter, L. W., 1972, Functional aspects of the selective depletion of lymphoid tissue by cyclophosphamide, Immunology 23: 493.PubMedGoogle Scholar
  251. Uchida, A. and Hoshino T., 1980, Reduction of suppressor-cells in cancer patients treated with OK-432 immunotherapy, Int. J. Cancer 26: 401.PubMedGoogle Scholar
  252. Umiel, T., and Trainin, N., 1974, Immunological enhancement of tumor growth by syngeneic thmus-derived lymphocytes, Transplantation 18: 244.PubMedGoogle Scholar
  253. Verrier-Jones, J., Klough, J. D., Klinburg, G. R., and Davis, P., 1981, The role of therapeutic plasmapheresis in the pneumatic diseases, J. Lab. Clin. Med. 97: 589.Google Scholar
  254. Voisin, G. A., 1972, Immunity and tolerance: A unified concept, Cell Immunol 2: 670.Google Scholar
  255. Waksman, B. H., and Tada, T., 1977, Specific and nonspecific suppressor T-cell factors derived from thymic lymphocytes, Cell Immunol 30: 189.PubMedGoogle Scholar
  256. Werner, D., Maier, G., and Lommel, R., 1973, A factor reducing protein synthesis from Ehrlich ascites cells, Eur. J. Cancer 9: 819.PubMedGoogle Scholar
  257. Witz, I. P., 1977, Tumor-bound immunoglobulins’ in situ expression of humoral immunity, Adv. Cancer Res. 25: 95.PubMedGoogle Scholar
  258. Wright, P. W., Hellstrôm, K. E., and Hellstrôm, I., 1976, Serotherapy of malignant melanoma, Med. Clin.N. Am 60: 607.PubMedGoogle Scholar
  259. Yamagishi, H., Nitta, K., and Umezawa, H., 1973, Immunosuppression induced with cell-free fluid of Ehrlich carcinoma ascites and its fractions, Gann 64: 83.Google Scholar
  260. Yamagishi, H., Pellis, N. R., and Kahan, B. D., 1983, Specific and nonspecific immunologic tumor growth facilitation, in: Immunobiology of Transplantation, Cancer and Pregnancy ( P. K. Ray, ed.), p. 179, Pergamon Press, New York.Google Scholar
  261. Yamamoto, J. K., Good, R. A., Johnson, H. M., Engleman, R., Tyler, R., Machida, K., Tran, X., and Day, N. K., 1983, Augmentation of serum interferon titre prior to remission of leukemia in cats treated with ex vivo immunoadsorption, Fed. Proc. 42: 838.Google Scholar
  262. Yonemoto, R. H., and Terasaki, P. I., 1972, Cancer immunotherapy with HLA compatible thoracic duct lymphocyte transplantation, Cancer 30: 1438.PubMedGoogle Scholar
  263. Zembla, M., Mytar, B., and Popiela, T., 1977, Depressed in vitro peripheral blood lymphocyte response to mitogens in cancer patients, Int. J. Cancer 19: 605.Google Scholar

Copyright information

© Plenum Press, New York 1985

Authors and Affiliations

  • Prasanta K. Ray
    • 1
  1. 1.Department of ImmunobiologyIndustrial Toxicology Research CenterLucknowIndia

Personalised recommendations